HUIDAGENE THERAPEUTICS ANNOUNCES IND ACTIVE FOR THE MULTINATIONAL TRIAL OF HG004 TO TREAT INHERITED BLINDNESS

HG004 is a one-time, direct-to-RPE treatment of inherited retinal disease caused by mutations in the RPE65 gene ∼ 10-fold lower vector doses than other AAV2 gene therapy clinical trials to be tested in this planned trial On track to initiate the multi-national trial by H1-2023 SHANGHAI...